Glaucomatous neurodegeneration and the concept of neuroprotection.
Glaucomatous neurodegeneration is a progressive pathological affair morphologically characterized by RGC death resulting in functional visual deterioration. Although a variety of primary insults ranging from mechanical trauma to ischemia to genetic susceptibility can initiate disease onset, apparently loss of trophic support and excitotoxin release remain the common themes responsible for neuronal damage and eventual cell death by apoptosis. The spread of this damage is perpetuated by secondary degeneration that allows directly injured neurons to release noxious and degenerative substances into the surrounding cells. Neuroprotection is a collective therapeutic approach the aim of which is to provide resilience to such neurons in an effort to prevent or delay progressive neuronal degeneration. At present, definitive neuroprotective therapy remains unachieved despite a variety of approaches having been defined and intensely pursued. However, the evolution in our understanding of glaucoma continues to offer reason for optimism. To this end, we remain unreservedly hopeful in the labor and committed work of dedicated investigators. We are all indebted to them.
Bautista
R D
RD
Department of Ophthalmology, Stanford University Medical Center, CA 94305, USA.
D017209:Apoptosis; D005901:Glaucoma / Q000150:complications*; D006801:Humans; D007429:Intraocular Pressure; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009896:Optic Atrophy / Q000209:etiology* / Q000473:pathology / Q000517:prevention & control*; D009900:Optic Nerve / Q000473:pathology; D012165:Retinal Ganglion Cells / Q000473:pathology
D018696:Neuroprotective Agents